LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
28,541,400
28,541,400
28,318,400
24,539,800
22,319,500
Cost of revenue
6,629,800
6,629,800
7,312,800
5,483,300
4,721,200
Gross profit
21,911,600
21,911,600
21,005,600
19,056,500
17,598,300
Operating expenses
Research development
7,190,800
7,190,800
7,025,900
6,085,700
5,595,000
Selling general and administrative
6,440,400
6,440,400
6,431,600
6,121,200
6,213,800
Total operating expenses
13,631,200
13,631,200
13,457,500
12,206,900
11,808,800
Operating income or loss
8,280,400
8,280,400
7,548,100
6,849,600
5,789,500
Interest expense
331,600
331,600
339,800
359,600
400,600
Total other income/expenses net
-1,205,200
-1,205,200
-1,078,200
706,900
-203,400
Income before tax
6,806,400
6,806,400
6,155,500
7,229,900
5,265,900
Income tax expense
561,600
561,600
573,800
1,036,200
628,000
Income from continuing operations
6,244,800
6,244,800
5,581,700
6,193,700
4,637,900
Net income
6,244,800
6,244,800
5,581,700
6,193,700
8,318,400
Net income available to common shareholders
6,244,800
6,244,800
5,581,700
6,193,700
8,318,400
Basic EPS
-
6.93
6.15
6.82
8.93
Diluted EPS
-
6.90
6.12
6.79
8.89
Basic average shares
-
901,736
906,963
907,634
931,059
Diluted average shares
-
904,619
911,681
912,505
935,684
EBITDA
-
8,280,400
7,548,100
6,849,600
5,789,500